Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Khaberni - A medical study has revealed promising results in treating moderate to severe psoriasis, one of the most ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET –SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) ...

Please provide your email address to receive an email when new articles are posted on . 85.1% of patients achieved PASI 90 and 52.3% achieved PASI 100 at week 256. The rates of treatment-emergent ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

MOBILE, Ala. (WALA) -There is now a new treatment option for the estimated 2 million people in the United States living with moderate-to-severe plaque psoriasis whose symptoms may make day-to-day life ...

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint was ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Decreased coronary flow was associated with severe psoriasis, according to one study. The largest study to date on the relationship between severe psoriasis and coronary microvascular dysfunction (CMD ...